nvista Holdings Corporation (NYSE: NVST) (“Envista”) will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025. Envista is moving the time of the conference call and will now discuss these results beginning at 2:30 PM PT on the same date. The call will last approximately one hour.
The call and the accompanying slide presentation will be webcast on the “Investors” section of Envista’s website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You can access the conference call by dialing 800-225-9448 within the U.S. or +1 203-518-9708 outside the U.S. a few minutes before 2:30 PM PT and referencing conference ID #7185081.
Envista’s earnings press release, the webcast slides, and other related presentation materials will be posted to the “Investors” section of Envista’s website before the conference call and will remain available following the call.
About Envista Holdings Corporation
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services.
Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists’ clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile.
With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry.
Source: www.envistaco.com
Periodontology 10 September 2025
To update the findings of a systematic review from the year 2016 on the evidence for the accuracy and potential benefits of cone beam computed tomography (CBCT) in periodontal diagnostics.
Oral carcinogenesis is a multifactorial process involving numerous genetic events that alter normal functions of oncogenes and tumour suppressor genes.
New surgical kits, a 6.0-mm implant, and upgraded accessories elevate the clinical ease and versatility of the company’s flagship system.
Oral surgery 24 May 2024
Dental autotransplantation (AT) is defined as the transplantation of a tooth from one site to a different site in the oral cavity of the same individual.
On Monday, February 5, 2024, the American Dental Association (ADA) updated their opioid prescribing guidelines for dental procedures in adults and adolescents (over 12 years of age.)
Prosthodontics 17 November 2025
The purpose of this report is to describe a new technique to fabricate and deliver an implant-supported fixed prosthesis to the patient on the day of surgery, and to propose a protocol for the...
Editorials 17 November 2025
The Langkamp Allison Award recognizes a Pitt Dental Medicine third-year dental student interested in pursuing a career in dental education.
Products 17 November 2025
VELMENI today unveiled VELMENI Voice, an AI-driven voice recognition tool designed to transform periodontal charting and clinical documentation.
News 17 November 2025
Angelalign Technology Inc. (6699.HK) (“Angel”) recently announced the expansion of its flexible iOrtho platform to include direct integration with the Dexis, Shining 3D, and Panda scanners.
News 17 November 2025
Following the first FDA clearance for technology that measures internal mobility in teeth, Perimetrics CEO and Chairman Robert Hayman is once again leading dentistry into a new era with InnerView, a...